Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy (INITIATE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insulin naive and failing OAD therapy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Insulin naive Type 2 diabetes
Currently treated with OADs alone or combined with other treatment for at least 3 months
BMI below 40 kg/m2 and body weight below 125 kg
HbA1c greater than or equal to 8%
Inability to tolerate metformin or contradictions to its use
Pregnant, breastfeeding or intention of becoming pregnant